MATTER’s Post

Implandata Ophthalmic Products made the cut as a finalist in the Chronic Disease Management track of the prestigious Health Tech Challengers award 2023. We upgrade the management of #glaucoma patients into the digital age with our breakthrough #EYEMATE system for remote disease monitoring and management. The product is CE marked and has obtained FDA Breakthrough Device Designation. Safety and performance has been demonstrated in several long-term studies. CPT Codes for remote patient monitoring are applicable, ensuring recurring and sustainable revenues for eye care specialists and Implandata. #Glaucoma is an incurable chronic eye disease, affecting 90 million people worldwide today. Increased eye pressure leads to permanent loss of eyesight of glaucoma patients. Despite a wealth of treatment options to control eye pressure, millions of patients are at risk to lose eyesight and eventually go blind, as eye pressure monitoring and thus therapy effectiveness control has basically not changed in the last 70 years. blind. We are changing this with our solution for personalized glaucoma care.

Introducing the groundbreaking Tech Hubs Program, set to catalyze entrepreneurship and innovation across every corner of America. This visionary initiative is poised to transform not just the tech landscape but also the future economic prospects of countless communities. 🚀💡 The Tech Hubs Program is not just a game-changer; it's a nation-builder. By fostering innovation, supporting startups, and nurturing local talent, it will unlock the potential for growth and prosperity in regions often overlooked. With a keen focus on inclusivity and diversity, this program is designed to ensure that every aspiring entrepreneur, regardless of background or location, has a shot at success. 💼🌆 What can you expect from this groundbreaking endeavor? Enhanced access to cutting-edge technology, incubators, and mentorship networks, providing a launchpad for budding startups to thrive. By nurturing local innovation, the Tech Hubs Program will empower America's regions to become leaders in emerging technology fields. 🌟📈 From revitalizing rural communities to boosting urban tech ecosystems, the ripple effects of this program are bound to be profound. It's not just about innovation; it's about reinvigorating local economies, creating jobs, and fostering a sense of hope and possibility. 🌎🌐 #TechHubsProgram #InnovationAcrossAmerica #Entrepreneurship #TechEcosystem #InclusiveInnovation #EconomicProsperity #FutureofTech #GameChanger #Intellectualproperty #trademarks #IP #Business #Register #Innovation #Brand #startups

After a year of strong growth, our unicorn portfolio hims & hers is moving into preventative cardiovascular health with its new approach: Heart Health by Hims. 🫀🩺 To accomplish this, the startup has established a strategic cooperation with the American College of Cardiology (ACC). Founder Andrew Dudum: “Cardiovascular disease may be one of our biggest opportunities yet. While everyone is trying to solve the problem, what’s most exciting to me is that we can leverage what we’ve been doing over the last six years to attack the issue in an interesting way. We already have tens of thousands of men coming to us every week for one of the more noticeable indicators of cardiovascular disease, which is erectile dysfunction.” Read the full Forbes story here: https://lnkd.in/grWkCt_Q #healthcare #venturecapital #startups #founders #vc #vcfunding

The stratified care approach to low back pain (STarTBack) approach generates more than £226 for every £1 spent to implement it, according to a recent report by the RAND corporation https://lnkd.in/dyzVxNzf For more information about STarT Back visit https://lnkd.in/dCCZ7f6C #backpain #startback

We are celebrating the successful closing of an additional $2.32 Million in Seed Plus funding, closing this round out $500,000 oversubscribed at $5 Million to address underserved #pelvichealth issues. This milestone reflects progress toward our mission to empower women & clinicians with a new gold standard in conservative care for #urinaryincontinence. We extend our deep appreciation to our outstanding partner, Boomerang Ventures for leading this investment round, and we warmly welcome new investors Pier 70 Ventures, Life Science Angels, Orange County Tech Coast Angels MedTech, and Blue Pacific Capital! "Completing this round is an important step in continuing Pelvital's unwavering dedication to provide women with innovative solutions for pelvic health, including the treatment of SUI," says Lydia Zeller, President and CEO of Pelvital. "This funding will play a crucial role in accelerating our commercialization of Flyte with a strong emphasis on expanding payor coverage, enhancing clinical education and clinician awareness, and advocating for upstream screening for UI in primary care and OB/GYN." With this close we are honored to welcome Preetha Ram, PhD, Managing Partner at Pier 70 Ventures, to the Pelvital Board of Directors.   "Joining Pelvital's Board alongside this investment round is truly an honor," she shares. "Pier 70 and I are thrilled to be part of this transformational opportunity, as Pelvital's mission aligns beautifully with our dedication to support disruptive technologies that shake up the status quo in healthcare. Pelvital's pioneering work is shaping a future where women's health receives the attention and innovation it deserves with novel medical devices like Flyte." With two published clinical trials validating Flyte's efficacy, we're excited to offer a groundbreaking treatment option for women. Learn more at Flytetherapy.com. #funding #Innovation #WomenInHealthcare Read the full release here: https://lnkd.in/ggkavYRq

Here is a perfect lesson on entrepreneurship! So proud of Sam and the team at Ayble Health.

Strengthening The First Line Of Defence For Newborn Cardiac Health US FDA Breakthrough Device Designation was granted to our Incu-Bio company Bloom Standard’s RAPIDscan – a portable, AI-powered system that automates ultrasound imaging for detecting heart disease in newborn children! Early diagnosis is key to preventing life-threatening conditions. RAPIDscan therefore advances infant healthcare by offering an affordable, easy-to-use solution for a wider community. The designation is a huge encouragement as it not only unlocks a faster track to market, but is also credible proof to the device’s novelty, uniqueness and impact.   Are you a #biomed #startup? Join us to transform healthcare: stp.hk/48TOMDy #HKSTP #PropellingSuccess

EarliTec Diagnostics Secures $21.5M in Series B Funding for Groundbreaking Autism Diagnostic Tool Development! 🌟 EarliTec Diagnostics, a pioneer in healthcare technology, has successfully raised an impressive $21.5 million in Series B funding. The funding, spearheaded by Nexus NeuroTech Ventures and Venture Investors Health Fund, marks a significant milestone for the company. This substantial investment will propel the commercialization of EarliPoint Evaluation, a cutting-edge diagnostic tool, and will further advance product development initiatives. Notably, the focus will be on pioneering research and development efforts for a revolutionary autism diagnostic and assessment tool tailored for toddlers. Stay tuned for more updates on this game-changing development! #EarliTecDiagnostics #SeriesBFunding #HealthcareInnovation #AutismDiagnosticTool #VentureInvestors #NexusNeuroTechVentures #HealthTechRevolution #EarliPointEvaluation #NewsNowNation 🌐

Are you a health start-up company with a groundbreaking solution that addresses care- and cure-related treatments for individuals with Spinal Cord Injuries (SCI)? We have fantastic news for you! We are delighted to announce the PRAXIS Acceleration Program 2023, a transformative opportunity tailored to empower health innovators focused on enhancing the overall quality of life for individuals with SCI. If your venture aims to revolutionize care, cure, or improve the well-being of individuals with SCI, this program is tailor-made for you. Tag your fellow health innovators, start-ups, and anyone who could benefit from this specialized opportunity. Together, let's make a lasting impact on SCI care and contribute to a better quality of life for individuals in need. 🔗 Apply Now: https://lnkd.in/gxkEUzAc #PRAXIS #AccelerationProgram #HealthStartups #SpinalCordInjuries #SCI #HealthcareInnovation #QualityOfLife #Mentorship #DemoDay #ApplyNow

The Schwartz Fund is on a roll! Three of my "portfolio" companies recently announced funding rounds: First, Gavin Buchanan and the PatchRx team closed their Series A to fuel growth of their smart pill bottle cap solution that leverages data to help drive medication adherence. PatchRx was one of my first investments, and it has been great to watch Gavin and team have such success. https://lnkd.in/erFWPN2P Next, congrats to Ruby Gadelrab Tudor and MDisrupt for completing their Seed Round. As digital health matures, MDisrupt's mission of enabling health tech companies to build, commercialize, and scale responsibly comes at a critical time. Ruby is an awesome founder and tremendous asset to the ecosystem. https://lnkd.in/ei3jDW57 Finally, huge news from Nick Aubin and Commons Clinic team as detailed in another great scoop from Erin Brodwin! Next generation, truly value-based MSK care remains a passion of mine, and Nick and his team get it. Can't wait to see how CC continues to evolve, prove its model, and expand! https://lnkd.in/eQT5Z_Qi Having gotten to know these companies and their founders a bit, I appreciate the hard work it takes to get to this point. Closing a round after riding the rollercoaster that is early-stage startup life is cause for celebration. The best part? I'm confident these companies are just getting started and aren't letting funding round announcements define them or their vision. If I have an investment thesis, it's to find humble, earnest founders working on high level solutions. Having one foot in the clinical world and one foot in the startup/innovation world gives me a unique perspective. I prefer good people solving real problems. I have a sneaking suspicion Schwartz Fund isn't done yet. I anticipate big things from my other portcos. Healent continues to quietly build momentum and experience rapid organic growth while offering a top-notch patient engagement platform. (Anoop Adya and Mike Palackdharry) PrecisionOS was featured on CNN and CNBC recently and is racking up partnerships with teaching institutions and MSK vendors to bring its novel approach to VR surgical training to the masses. (Danny Goel, MD) Ease is refining its "Shopify for Health" approach to support self-employed clinicians at the perfect time. Mario Amaro's drive and passion is infectious. Last, but in no way least, I'm certain Quinn Wang, MD is hard at work building Quadrant Eye (YC W21) into the next generation eye care platform we desperately need. I anticipate big news soon. Congrats to all, and thanks for allowing me to tag along for the ride. #msk #healthcareinnovation #vbc #healthcare #digitalhealth #healthcaretechnology